Danske Bank A S raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 8.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 171,842 shares of the pharmaceutical company’s stock after purchasing an additional 13,778 shares during the period. Danske Bank A S owned 0.07% of Vertex Pharmaceuticals worth $89,841,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of the stock. Guidance Capital Inc. grew its stake in Vertex Pharmaceuticals by 0.9% in the 3rd quarter. Guidance Capital Inc. now owns 2,230 shares of the pharmaceutical company’s stock valued at $1,234,000 after buying an additional 19 shares during the last quarter. Bangor Savings Bank lifted its position in Vertex Pharmaceuticals by 0.4% during the second quarter. Bangor Savings Bank now owns 4,470 shares of the pharmaceutical company’s stock worth $2,220,000 after acquiring an additional 20 shares during the last quarter. Trust Point Inc. lifted its position in Vertex Pharmaceuticals by 2.7% during the second quarter. Trust Point Inc. now owns 793 shares of the pharmaceutical company’s stock worth $394,000 after acquiring an additional 21 shares during the last quarter. Integrated Advisors Network LLC boosted its holdings in shares of Vertex Pharmaceuticals by 1.4% during the third quarter. Integrated Advisors Network LLC now owns 1,625 shares of the pharmaceutical company’s stock worth $850,000 after acquiring an additional 22 shares during the period. Finally, Glenview Trust Co boosted its holdings in shares of Vertex Pharmaceuticals by 0.3% during the third quarter. Glenview Trust Co now owns 6,773 shares of the pharmaceutical company’s stock worth $3,541,000 after acquiring an additional 22 shares during the period. 90.96% of the stock is owned by institutional investors.
Vertex Pharmaceuticals Stock Performance
NASDAQ VRTX traded down $4.02 during trading on Friday, reaching $538.60. The company’s stock had a trading volume of 755,937 shares, compared to its average volume of 1,580,871. The company has a current ratio of 2.34, a quick ratio of 1.89 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $136.56 billion, a price-to-earnings ratio of 34.66, a price-to-earnings-growth ratio of 2.87 and a beta of 0.28. Vertex Pharmaceuticals Incorporated has a 12 month low of $412.27 and a 12 month high of $568.67. The firm has a 50 day moving average price of $522.37 and a 200 day moving average price of $483.84.
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last announced its earnings results on Monday, November 2nd. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.06). Vertex Pharmaceuticals had a return on equity of 21.98% and a net margin of 30.70%. The business had revenue of $3.44 billion for the quarter, compared to analyst estimates of $3.42 billion. During the same quarter in the previous year, the company earned $4.80 EPS. The business’s revenue for the quarter was up 11.8% on a year-over-year basis. As a group, equities analysts anticipate that Vertex Pharmaceuticals Incorporated will post 16.10 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several equities analysts have recently commented on the company. Evercore upped their target price on Vertex Pharmaceuticals from $535.00 to $600.00 and gave the company an “outperform” rating in a research report on Wednesday, September 2nd. JPMorgan Chase & Co. lifted their price target on Vertex Pharmaceuticals from $560.00 to $570.00 and gave the stock an “overweight” rating in a report on Tuesday, November 3rd. Scotiabank boosted their price target on Vertex Pharmaceuticals from $558.00 to $660.00 and gave the company a “sector outperform” rating in a research note on Tuesday, November 3rd. Truist Financial upped their price objective on Vertex Pharmaceuticals from $560.00 to $565.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Finally, Cantor Fitzgerald increased their price objective on Vertex Pharmaceuticals from $595.00 to $619.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 3rd. One analyst has rated the stock with a Strong Buy rating, twenty-five have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $596.44.
Read Our Latest Stock Report on Vertex Pharmaceuticals
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF). Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.
Further Reading
- Five stocks we like better than Vertex Pharmaceuticals
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
